Table 2.

Analysis of survival

	From start of EGFR-TKI to RECIST PD* Median (95% CI)	From start of EGFR-TKI to death† Median (95% CI)	From RECIST PD to death† Median (95% CI)
	Months
All patients
Group A	8.0 (7.2 to 8.8)	17.5 (15.0 to 20.9)	8.9 (6.2 to 10.7)
Group B	8.8 (7.7 to 10.1)	25.6 (21.7 to 30.8)	14.6 (12.4 to 16.2)
Group C	11.5 (10.0 to 13.3)	28.9 (24.6 to 39.2)	15.3 (12.5 to 20.4)
Group D	–	18.3 (14.1 to 24.2)	–
Patients with PR/CR for the first-line EGFR-TKI
Group A	8.7 (7.8 to 9.9)	19.9 (17.0 to 23.2)	9.5 (6.9 to 11.4)
Group B	10.8 (9.1 to 13.1)	33.8 (26.8 to 36.7)	17.7 (14.6 to 21.6)
Group C	11.7 (10.0 to 13.7)	29.8 (25.6 to 39.2)	16.2 (12.7 to 22.8)
Group D	–	24.2 (15.5 to 34.4)	–

*Patient death from any cause is treated as censored case.

†Patients were censored at their final day of the follow-up.

CR, complete response; EGFR, epidermal growth factor receptor; OS, overall survival; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; TKI, tyrosine kinase inhibitor.